KR102687212B1 - Hiv 감염의 예방 또는 치료를 위한 3특이성 및/또는 3가 결합 단백질 - Google Patents

Hiv 감염의 예방 또는 치료를 위한 3특이성 및/또는 3가 결합 단백질 Download PDF

Info

Publication number
KR102687212B1
KR102687212B1 KR1020187014534A KR20187014534A KR102687212B1 KR 102687212 B1 KR102687212 B1 KR 102687212B1 KR 1020187014534 A KR1020187014534 A KR 1020187014534A KR 20187014534 A KR20187014534 A KR 20187014534A KR 102687212 B1 KR102687212 B1 KR 102687212B1
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
sequence
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187014534A
Other languages
English (en)
Korean (ko)
Other versions
KR20180063336A (ko
Inventor
즈-융 양
개리 제이. 네이블
링 쉬
로니 웨이
화웨이 추
요헨 베닝가
요헨 크루이프
에르콜레 라오
불프 디르크 로이슈너
크리스티안 바일
크리스티안 랑게
마크 코너스
존 알. 마스콜라
리차드 에이. 쿱
징허 황
니콜 에이. 도리아-로즈
퉁칭 저우
피터 디. 쾅
영 도 권
아마렌드라 페구
망가이아르카라시 아소칸
Original Assignee
사노피
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피, 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 filed Critical 사노피
Publication of KR20180063336A publication Critical patent/KR20180063336A/ko
Application granted granted Critical
Publication of KR102687212B1 publication Critical patent/KR102687212B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C07K16/1063—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020187014534A 2015-10-25 2016-10-24 Hiv 감염의 예방 또는 치료를 위한 3특이성 및/또는 3가 결합 단백질 Active KR102687212B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562246113P 2015-10-25 2015-10-25
US62/246,113 2015-10-25
EP16305211.1 2016-02-24
EP16305211 2016-02-24
US201662322029P 2016-04-13 2016-04-13
US62/322,029 2016-04-13
US201662331169P 2016-05-03 2016-05-03
US62/331,169 2016-05-03
PCT/US2016/058540 WO2017074878A1 (en) 2015-10-25 2016-10-24 Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection

Publications (2)

Publication Number Publication Date
KR20180063336A KR20180063336A (ko) 2018-06-11
KR102687212B1 true KR102687212B1 (ko) 2024-07-19

Family

ID=55588187

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187014534A Active KR102687212B1 (ko) 2015-10-25 2016-10-24 Hiv 감염의 예방 또는 치료를 위한 3특이성 및/또는 3가 결합 단백질

Country Status (30)

Country Link
US (4) US20190054182A1 (cg-RX-API-DMAC7.html)
EP (2) EP3365366B1 (cg-RX-API-DMAC7.html)
JP (3) JP7169190B2 (cg-RX-API-DMAC7.html)
KR (1) KR102687212B1 (cg-RX-API-DMAC7.html)
CN (4) CN117069855A (cg-RX-API-DMAC7.html)
AR (1) AR106466A1 (cg-RX-API-DMAC7.html)
AU (2) AU2016347058B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018008011A2 (cg-RX-API-DMAC7.html)
CA (1) CA3002664A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018001065A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018005337A2 (cg-RX-API-DMAC7.html)
CR (1) CR20180288A (cg-RX-API-DMAC7.html)
DO (1) DOP2018000102A (cg-RX-API-DMAC7.html)
EA (1) EA201891028A1 (cg-RX-API-DMAC7.html)
ES (1) ES2894304T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211528T1 (cg-RX-API-DMAC7.html)
HU (1) HUE056608T2 (cg-RX-API-DMAC7.html)
IL (2) IL301140A (cg-RX-API-DMAC7.html)
MA (1) MA42641A1 (cg-RX-API-DMAC7.html)
MX (2) MX2018005048A (cg-RX-API-DMAC7.html)
MY (1) MY192278A (cg-RX-API-DMAC7.html)
PE (1) PE20181167A1 (cg-RX-API-DMAC7.html)
PH (1) PH12018500873A1 (cg-RX-API-DMAC7.html)
PL (1) PL3365366T3 (cg-RX-API-DMAC7.html)
RS (1) RS62437B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201803324VA (cg-RX-API-DMAC7.html)
SI (1) SI3365366T1 (cg-RX-API-DMAC7.html)
TW (3) TW202442675A (cg-RX-API-DMAC7.html)
UY (1) UY36965A (cg-RX-API-DMAC7.html)
WO (1) WO2017074878A1 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015048770A2 (en) 2013-09-30 2015-04-02 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
WO2015128846A1 (en) * 2014-02-28 2015-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region
ES2894304T3 (es) * 2015-10-25 2022-02-14 Sanofi Sa Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH
EP4011911A1 (en) * 2015-11-03 2022-06-15 The United States of America as represented by The Secretary Department of Health and Human Services Neutralizing antibodies to hiv-1 gp41 and their use
EP3443006B1 (en) 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
MY192090A (en) * 2016-04-13 2022-07-26 Sanofi Sa Trispecific and/or trivalent binding proteins
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
WO2018151841A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
KR102654105B1 (ko) 2017-02-17 2024-04-04 사노피 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
EP3601334A4 (en) * 2017-03-27 2021-03-31 The Wistar Institute Of Anatomy And Biology Dna antibody constructs for use against hiv
JP7009517B2 (ja) 2017-06-21 2022-01-25 ギリアード サイエンシーズ, インコーポレイテッド Hiv gp120およびcd3を標的とする多重特異性抗体
CN111788225B (zh) 2017-10-10 2025-02-18 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
WO2019123262A1 (en) * 2017-12-18 2019-06-27 VIIV Healthcare UK (No.5) Limited Antigen binding polypeptides
CN111819196B (zh) * 2017-12-21 2022-10-28 纽约市哥伦比亚大学理事会 双特异性hiv-1中和抗体
IL275536B2 (en) 2018-01-12 2025-06-01 Genzyme Corp Methods for quantification of polypeptides
EP3797118A4 (en) 2018-05-22 2022-06-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
TWI856979B (zh) * 2018-10-09 2024-10-01 法商賽諾菲公司 三特異性抗cd38、抗cd28和抗cd3結合蛋白和用於治療病毒感染的使用方法
EP3883962A4 (en) * 2018-11-21 2023-04-12 Beth Israel Deaconess Medical Center, Inc. ANTIBODY THERAPIES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV)
TW202104274A (zh) * 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療hiv感染之三特異性及/或三價結合蛋白
JP7664175B2 (ja) * 2019-04-09 2025-04-17 サノフイ 三重特異性結合性タンパク質、方法、およびその使用
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
MX2022004881A (es) 2019-10-25 2022-05-16 Sanofi Sa Metodos para analizar el emparejamiento incorrecto de cadenas en proteinas de union multiespecificas.
US20230203466A1 (en) * 2020-04-03 2023-06-29 Medgenome Inc. Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
JP7518286B2 (ja) * 2020-08-25 2024-07-17 ギリアード サイエンシーズ, インコーポレイテッド Hivを標的とする多重特異性抗原結合分子及び使用方法
EP4408892A4 (en) * 2021-09-29 2025-11-19 Modex Therapeutics Inc Antigen-binding polypeptides, antigen-binding polypeptide complexes, and their methods of use in HIV
TW202330594A (zh) * 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
CN118317979A (zh) * 2021-09-29 2024-07-09 摩德斯医疗股份有限公司 抗原结合多肽、抗原结合多肽复合物及其使用方法
AU2024386429A1 (en) 2023-11-22 2026-05-21 Mabylon Ag Multispecific anti-allergen antibodies and uses thereof
AU2023474055A1 (en) 2023-11-23 2026-06-04 Mabylon Ag Multispecific anti-allergen antibodies and uses thereof
WO2025238419A1 (en) 2024-05-17 2025-11-20 Sanofi Methods of treating cancer using trispecific binding proteins targeting her2-expressing tumors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135345A1 (en) 2011-03-28 2012-10-04 Sanofi Dual variable region antibody-like binding proteins having cross-over binding region orientation
WO2013163427A1 (en) * 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
WO2014116846A2 (en) * 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
US20140213772A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338518C (en) 1987-09-23 1996-08-13 Joyce M. Zarling Antibody heteroconjugates for the killing of hiv-infected cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
EP1361892A4 (en) 2001-01-17 2004-10-13 Trubion Pharmaceuticals Inc BINDING DOMAIN FUSION PROTEIN Immunoglobulin
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
EP2014680A1 (en) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
US9175070B2 (en) 2009-09-25 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
CN103282385A (zh) 2010-11-12 2013-09-04 美国洛克菲勒大学 用于hiv治疗的融合蛋白
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン(シャンハイ)コーポレイション リミテッド 多重特異性Fab融合タンパク質および使用法
CN112225798B (zh) * 2011-05-17 2023-07-18 洛克菲勒大学 人类免疫缺陷病毒中和抗体及其使用方法
CN103906533A (zh) * 2011-11-07 2014-07-02 米迪缪尼有限公司 多特异性和多价结合蛋白及其用途
CN104080805B (zh) 2011-11-07 2017-02-22 美国政府健康及人类服务部 gp41中和性抗体及其用途
CN104271597B (zh) 2011-12-08 2018-05-25 美国政府(由卫生和人类服务部的部长所代表) Hiv-1的中和抗体及其用途
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US20150239991A1 (en) * 2012-09-25 2015-08-27 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
CN104955847A (zh) 2012-12-04 2015-09-30 马里兰州大学(巴尔的摩) HIV-1 Env结合抗体、融合蛋白及其使用方法
EP2931318A4 (en) 2012-12-13 2016-07-20 Univ Pennsylvania DNA ANTIBODY CONSTRUCTS AND METHODS FOR USE THEREOF
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
CN110437337B (zh) * 2013-02-26 2024-07-30 罗切格利卡特公司 双特异性t细胞活化性抗原结合分子
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CA2904407A1 (en) 2013-03-15 2014-09-18 Abbvie Inc. Dual specific binding proteins directed against tnf.alpha.
EP3027755B1 (en) 2013-08-02 2019-10-09 The Regents of The University of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
AP2016009222A0 (en) 2013-11-04 2016-05-31 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
PL3122781T3 (pl) 2014-03-28 2020-06-15 Xencor, Inc. Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
BR112017004270B1 (pt) 2014-09-04 2023-03-07 Stemcell Technologies Inc Método de ativação de células t ou células nk
AR103488A1 (es) 2015-01-23 2017-05-10 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
TWI704229B (zh) 2015-05-20 2020-09-11 美商寬騰矽公司 核酸定序方法
WO2016196740A1 (en) 2015-06-02 2016-12-08 The Rockefeller University Tri-specific antibodies for hiv therapy
JP6991131B2 (ja) 2015-09-22 2022-02-03 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Hiv感染症を処置するためにt細胞を再度方向付ける方法
ES2894304T3 (es) 2015-10-25 2022-02-14 Sanofi Sa Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH
CN105837688B (zh) 2015-11-20 2019-02-26 北京大学深圳研究生院 单域抗体及其编码基因,免疫毒素及其编码基因、制备方法、表达载体、应用,及宿主细胞
JP6732915B2 (ja) 2015-12-15 2020-07-29 ギリアード サイエンシーズ, インコーポレイテッド ヒト免疫不全ウイルス中和抗体
MY192090A (en) 2016-04-13 2022-07-26 Sanofi Sa Trispecific and/or trivalent binding proteins
EP3443006B1 (en) 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
EP3575319A4 (en) 2016-12-30 2021-03-10 Shanghai Sinobio Biotech Co., Ltd. BIFUNCTIONAL MOLECULE AND USE OF IT
WO2018151841A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
KR102654105B1 (ko) 2017-02-17 2024-04-04 사노피 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
EP3601334A4 (en) 2017-03-27 2021-03-31 The Wistar Institute Of Anatomy And Biology Dna antibody constructs for use against hiv
CN111788225B (zh) 2017-10-10 2025-02-18 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
TWI856979B (zh) 2018-10-09 2024-10-01 法商賽諾菲公司 三特異性抗cd38、抗cd28和抗cd3結合蛋白和用於治療病毒感染的使用方法
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135345A1 (en) 2011-03-28 2012-10-04 Sanofi Dual variable region antibody-like binding proteins having cross-over binding region orientation
WO2013163427A1 (en) * 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
US20140213772A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
WO2014116846A2 (en) * 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response

Also Published As

Publication number Publication date
PH12018500873A1 (en) 2018-11-12
US11129905B2 (en) 2021-09-28
TW201730210A (zh) 2017-09-01
CN116675776A (zh) 2023-09-01
CA3002664A1 (en) 2017-05-04
HRP20211528T1 (hr) 2021-12-24
JP7328267B2 (ja) 2023-08-16
BR112018008011A2 (en) 2018-10-30
CN109311966B (zh) 2023-03-10
JP2018537966A (ja) 2018-12-27
WO2017074878A1 (en) 2017-05-04
JP7169190B2 (ja) 2022-11-10
CN116789841A (zh) 2023-09-22
TW202219064A (zh) 2022-05-16
AU2016347058A1 (en) 2018-06-14
EP3365366B1 (en) 2021-07-14
JP2021072847A (ja) 2021-05-13
US20220226495A1 (en) 2022-07-21
HUE056608T2 (hu) 2022-02-28
HK1253385A1 (zh) 2019-06-14
IL301140A (en) 2023-05-01
JP7724814B2 (ja) 2025-08-18
US11779651B2 (en) 2023-10-10
SI3365366T1 (sl) 2022-02-28
CN117069855A (zh) 2023-11-17
EA201891028A1 (ru) 2019-02-28
UY36965A (es) 2017-05-31
CL2018001065A1 (es) 2018-11-23
WO2017074878A8 (en) 2018-05-24
RS62437B1 (sr) 2021-11-30
KR20180063336A (ko) 2018-06-11
SG11201803324VA (en) 2018-05-30
AR106466A1 (es) 2018-01-17
CR20180288A (es) 2018-09-11
CN109311966A (zh) 2019-02-05
IL258822A (en) 2018-06-28
ES2894304T3 (es) 2022-02-14
TWI750139B (zh) 2021-12-21
IL258822B2 (en) 2023-08-01
US20200054765A1 (en) 2020-02-20
US20250312475A1 (en) 2025-10-09
NZ742825A (en) 2024-04-26
MX2022014631A (es) 2023-01-11
JP2023085476A (ja) 2023-06-20
MY192278A (en) 2022-08-16
PE20181167A1 (es) 2018-07-19
EP3365366A1 (en) 2018-08-29
MA42641A1 (fr) 2019-03-29
NZ781602A (en) 2025-07-25
PL3365366T3 (pl) 2022-01-31
AU2016347058B2 (en) 2023-11-09
EP3819310A1 (en) 2021-05-12
AU2024200395A1 (en) 2024-04-11
IL258822B1 (en) 2023-04-01
MX2018005048A (es) 2018-09-06
CO2018005337A2 (es) 2018-07-10
TW202442675A (zh) 2024-11-01
US20190054182A1 (en) 2019-02-21
DOP2018000102A (es) 2018-11-30

Similar Documents

Publication Publication Date Title
KR20180063336A (ko) Hiv 감염의 예방 또는 치료를 위한 3특이성 및/또는 3가 결합 단백질
KR102831970B1 (ko) 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
US20230340160A1 (en) Bispecific t cell activating antigen binding molecules
AU2018211985B2 (en) Tissue-specific Wnt signal enhancing molecules and uses thereof
CN109476732B (zh) 三特异性和/或三价结合蛋白
KR102361237B1 (ko) 코일드 코일 면역글로불린 융합 단백질 및 이것의 조성물
CN111954680B (zh) IL2Rβ/共同γ链抗体
KR102648966B1 (ko) Folr1 및 cd3에 대한 t 세포 활성화 이중특이적 항원 결합 분자
AU2021254602A1 (en) Humanized anti-MUC1* antibodies
KR20220167273A (ko) 항-코로나바이러스 항체 및 사용 방법
KR102096224B1 (ko) 폴리펩티드 구축물 및 이의 용도
KR20180054877A (ko) 공자극 tnf 수용체에 대해 4가를 갖는 이중특이적 항체
KR20150122761A (ko) T 세포 활성화 항원 결합 분자
KR20180053674A (ko) 공자극 tnf 수용체에 특이적인 이중특이성 항체
KR20150122203A (ko) T 세포 활성화 이중특이적 항원 결합 분자
KR20140114833A (ko) 신생아 Fc 수용체에 대해 향상된 결합을 지니는 변이체 Fc-폴리펩타이드
KR20220154710A (ko) 소형 유도 및 항법 제어(miniGNC) 항체-유사 단백질 및 이의 제조 및 사용 방법
CN113950484A (zh) 三特异性结合蛋白、其方法和用途
CN114096561A (zh) 使用交叉双重可变结构域(codv)形式用于治疗hiv感染的三特异性和/或三价结合蛋白
KR20230017815A (ko) 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
KR20230163485A (ko) 면역 이펙터 세포 재유도를 위한 물질 및 방법
KR20240036142A (ko) 3특이성 및/또는 3가 결합 단백질
CN113316587B (zh) 一种双特异性分子及其制备与用途
KR20230105972A (ko) 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
RU2820164C2 (ru) Триспецифические и/или тривалентные связывающие белки с применением кроссоверного формата с двойным вариабельным доменом (codv) для лечения инфекции, вызванной hiv

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000